Avantax Advisory Services Inc. Acquires 2,310 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Avantax Advisory Services Inc. boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 11.5% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,408 shares of the medical research company's stock after acquiring an additional 2,310 shares during the quarter. Avantax Advisory Services Inc.'s holdings in Thermo Fisher Scientific were worth $11,894,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the business. Nuance Investments LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $9,867,000. McKinley Carter Wealth Services Inc. increased its position in shares of Thermo Fisher Scientific by 15.7% during the 4th quarter. McKinley Carter Wealth Services Inc. now owns 14,883 shares of the medical research company's stock valued at $7,900,000 after purchasing an additional 2,021 shares during the last quarter. North Growth Management Ltd. bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at about $8,599,000. QRG Capital Management Inc. increased its position in shares of Thermo Fisher Scientific by 0.8% during the 4th quarter. QRG Capital Management Inc. now owns 25,681 shares of the medical research company's stock valued at $13,631,000 after purchasing an additional 208 shares during the last quarter. Finally, Invst LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $215,000. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have commented on TMO shares. Citigroup started coverage on Thermo Fisher Scientific in a research note on Monday, March 18th. They issued a "neutral" rating and a $620.00 price target on the stock. HSBC lifted their price target on Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a "buy" rating in a research note on Tuesday, April 30th. Evercore ISI lifted their price target on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an "outperform" rating in a research note on Thursday, April 4th. The Goldman Sachs Group lifted their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a "buy" rating in a research note on Wednesday, April 10th. Finally, Royal Bank of Canada lifted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an "outperform" rating in a research report on Thursday, February 1st. Five equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $607.35.

Thermo Fisher Scientific Stock Down 0.4 %

Thermo Fisher Scientific stock traded down $2.33 during mid-day trading on Monday, hitting $590.70. The company had a trading volume of 920,079 shares, compared to its average volume of 1,540,064. The company has a current ratio of 1.70, a quick ratio of 1.33 and a debt-to-equity ratio of 0.68. The stock's 50 day moving average price is $576.27 and its two-hundred day moving average price is $537.88. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The company has a market capitalization of $225.48 billion, a PE ratio of 37.89, a price-to-earnings-growth ratio of 2.46 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. The business had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. As a group, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 21.64 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a $0.39 dividend. The ex-dividend date was Thursday, March 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.35. Thermo Fisher Scientific's payout ratio is currently 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the business's stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total value of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of the company's stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the company's stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total value of $5,724,100.00. Following the sale, the chief executive officer now owns 123,816 shares of the company's stock, valued at approximately $70,873,516.56. The disclosure for this sale can be found here. Insiders sold 37,547 shares of company stock worth $21,541,269 over the last quarter. 0.34% of the stock is currently owned by insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.